Mimedx (MDXG) Liabilities and Shareholders Equity (2010 - 2026)

Mimedx has disclosed Liabilities and Shareholders Equity across 17 years of filings, most recently posting $281.0 million for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity fell 3.47% year-over-year to $281.0 million; the TTM figure through Jun 2026 stood at $1.3 billion (up 17.02% YoY), while the FY2025 annual figure was $342.7 million, up 29.83% from the prior year.
• Liabilities and Shareholders Equity came in at $281.0 million for Q2 2026 at Mimedx, down from $308.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $342.7 million in Q4 2025 to a low of $168.2 million in Q1 2023.
• Average Liabilities and Shareholders Equity over 5 years is $235.1 million, with a median of $234.6 million recorded in 2023.
• Year-over-year, Liabilities and Shareholders Equity dropped 9.87% in 2022 and surged 39.44% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $171.4 million in 2022, then jumped by 39.44% to $239.0 million in 2023, then gained by 10.4% to $263.9 million in 2024, then grew by 29.83% to $342.7 million in 2025, then dropped by 17.99% to $281.0 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $281.0 million in Q2 2026, $308.7 million in Q1 2026, and $342.7 million in Q4 2025.